Viridian director-linked funds granted 32,341 options

Viridian Therapeutics director-associated funds received a new stock option grant.

Rhea-AI Filing Summary

Viridian Therapeutics director-associated funds received a new stock option grant. An option over 32,341 shares of Viridian common stock was granted at an exercise price of $18.48 per share and expires on July 1, 2036.

The option vests in full on the earlier of July 1, 2027 or Viridian’s 2027 annual stockholder meeting, contingent on Tomas Kiselak continuing to serve on the board. Under an arrangement with Fairmount Funds Management LLC, the option and any related value are for Fairmount-managed investment vehicles, and Kiselak disclaims beneficial ownership.

Insider Trade Summary

Grant/Award: 32,341 shares

Grant/Award 1 txn

Insider Kiselak Tomas

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	32,341	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 32,341 contracts (Indirect, See Footnote)

Footnotes (2)

1. F1. The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.
2. F2. Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

Key Figures

Option grant size: 32,341 options Exercise price: $18.48 per share Expiration date: July 1, 2036 +2 more

5 metrics

Option grant size 32,341 options Stock Option (Right to Buy) covering 32,341 common shares

Exercise price $18.48 per share Conversion or exercise price of the stock option

Expiration date July 1, 2036 Option expiration date for the 32,341-share grant

Vesting trigger date July 1, 2027 Vests on earlier of July 1, 2027 or 2027 annual meeting

Post-grant derivative holdings 32,341 options Total options following transaction, held indirectly

Key Terms

Stock Option (Right to Buy), beneficial ownership, Board of Directors, annual meeting of stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

beneficial ownership financial

"The Reporting Person therefore disclaims beneficial ownership of the option"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Board of Directors financial

"subject to the Reporting Person's continued service on the Board of Directors"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

annual meeting of stockholders financial

"the Issuer's 2027 annual meeting of stockholders"

investment vehicles financial

"one or more investment vehicles managed by the Adviser"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the Viridian Therapeutics (VRDN) director-related entities receive in this report?

An entity associated with director Tomas Kiselak received a stock option over 32,341 Viridian common shares. The option is a compensation grant, not an open-market purchase, and is held for investment vehicles managed by Fairmount Funds Management LLC.

What are the key terms of the new Viridian Therapeutics (VRDN) stock option grant?

The option covers 32,341 Viridian common shares at an exercise price of $18.48 per share and expires on July 1, 2036. It represents indirect holdings linked to investment funds rather than a direct market transaction by the director.

When does the new Viridian Therapeutics (VRDN) option grant vest?

The option vests in full on the earlier of July 1, 2027 or Viridian’s 2027 annual meeting of stockholders. Vesting is conditioned on Tomas Kiselak’s continued service on the company’s board of directors through that vesting event.

Who ultimately benefits from the Viridian Therapeutics (VRDN) option grant reported for Tomas Kiselak?

Under an arrangement with Fairmount Funds Management LLC, the option and any net cash or stock from it benefit one or more Fairmount-managed investment funds. Kiselak is required to turn over such value and disclaims beneficial ownership of the option and underlying shares.

Is the Viridian Therapeutics (VRDN) option grant a market purchase or sale of shares?

No, it is a compensatory stock option grant, not a market trade. The transaction reflects an award of derivative securities linked to Viridian common stock rather than buying or selling shares on an exchange or in open-market transactions.

How many Viridian Therapeutics (VRDN) derivative securities does the director-linked entity hold after this grant?

After the grant, the reporting structure shows 32,341 stock options linked to Viridian common shares. These options are held indirectly for Fairmount-managed investment vehicles, with Kiselak disclaiming beneficial ownership of both the options and underlying shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kiselak Tomas

(Last) (First) (Middle)

C/O VIRIDIAN THERAPEUTICS, INC.

221 CRESCENT STREET, SUITE 103A

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Viridian Therapeutics, Inc.\DE [ VRDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$18.48	07/01/2026		A		32,341		(1)	07/01/2036	Common Stock	32,341	$0	32,341	I	See Footnote(2)

Explanation of Responses:

1. The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.

2. Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

	/s/ Jennifer Tousignant, Attorney-in-fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)